Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma.

Författare

Summary, in English

BACKGROUND: Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC. METHODS: Between 1993 and 1999 47 patients underwent PET before (PET(1)) and after (PET(2)) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years. RESULTS: Low and high MR FDG at PET(2), with median value as cutoff, was associated with complete remission in 96% and 62% (p =.007), with 5-year overall survival in 72% and 35% (p =.0042) and with local control in 96% and 55% (p =.002), respectively. CONCLUSIONS: FDG PET in the early phase of treatment of HNSCC is associated with tumor response, survival, and local control. Copyright 2002 John Wiley & Sons, Inc.

Ämne

  • Cancer and Oncology
  • Otorhinolaryngology
  • Radiology, Nuclear Medicine and Medical Imaging

Nyckelord

  • Fludeoxyglucose F 18/*diagnostic use/pharmacokinetics
  • Female
  • Head and Neck Neoplasms/mortality/*radionuclide imaging/*therapy
  • Human
  • Male
  • Middle Age
  • Predictive Value of Tests
  • Reproducibility of Results
  • Radiopharmaceuticals/*diagnostic use/pharmacokinetics
  • Squamous Cell/mortality/*radionuclide imaging/*therapy
  • Carcinoma
  • 80 and over
  • Aged

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1043-3074